Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Scientists may have unlocked a new milestone in cancer treatment. An individual who received CAR T-cell therapy has been in ...

Protheragen is an advanced CAR-T cell therapy service provider. With its extensive experience in cell therapy development and ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.